Nutricia is one of 19 partners in the LDD Consortium. Souvenaid® (containing the key nutrient combination "Fortasyn Connect®") was selected as the intervention product within the LDD study, on the basis of its results in an earlier EU project (LipiDiet, completed 2000-2005), and other early development work.
These results in patients with MCI support and extend findings from two previous randomised controlled trials of Souvenaid in patients with mild AD. We are pleased that this adds to the body of evidence for Souvenaid and we remain committed to ongoing and further clinical research.1,2
Visit the LipiDiDiet Consortium at http://www.lipididiet.eu